Alkem Laboratories Annual Report 2023-24

Alkem Laboratories' FY 2023-24 annual report details the company's strategic expansion across chronic diseases, acute segments, and emerging therapeutic areas. Key initiatives include the launch of Cetuxa biosimilar, entry into ophthalmology and CDMO services, and portfolio optimization driving productivity-led growth. The report highlights financial performance and commitment to innovation in the pharmaceutical sector since the company's 1973 inception.